Načítá se...
Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis
AIM: Leflunomide, via its active metabolite teriflunomide, is used in rheumatoid arthritis (RA) treatment, yet approximately 20 to 40% of patients cease due to toxicity. The aim was to develop a time‐to‐event model describing leflunomide cessation due to toxicity within a clinical cohort and to inve...
Uloženo v:
| Vydáno v: | Br J Clin Pharmacol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4693574/ https://ncbi.nlm.nih.gov/pubmed/26331989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12760 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|